Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
You may also be interested in...
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
Bio-Techne has reached an agreement to acquire Exosome Diagnostics, putting the firm in a stronger position in the emerging liquid biopsy and precision medicine spaces.
Asian investors' unrelenting pursuit of medtech ventures continued to crescendo in May. The participants in the largest round so far this year, the $300m series C by Illumina spin-out Grail, are all China-based funds.